⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7122548 | 0.78 | NPSR1 (0.31) | — | |
| SCHEMBL1760354 | 0.75 | — | — | |
| SCHEMBL6636831 | 0.73 | L3MBTL1 (0.39) | — | |
| SCHEMBL2699370 | 0.73 | — | — | |
| SCHEMBL12527323 | 0.72 | — | — | |
| SCHEMBL606948 | 0.71 | — | — | |
| SCHEMBL11017810 | 0.71 | ALDH1A1 (0.31) | — | |
| SCHEMBL12328388 | 0.69 | MEN1 (0.39) | — | |
| SCHEMBL961446 | 0.69 | CYP1A2 (0.32) | — | |
| SCHEMBL13608002 | 0.69 | EPHX1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230119612-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
| US-20200231638-A1 | STABILIZED ANTI-MICROBIAL PEPTIDES | DANA-FARBER CANCER INSTITUTE, INC. | 2020-07-23 | — | — | US | disclosed |
| US-10246491-B2 | Peptidomimetic macrocycles and use thereof in regulating HIF1alpha | AILERON THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20190071469-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2019-03-07 | — | — | US | disclosed |
| US-10023613-B2 | Peptidomimetic macrocycles as modulators of MCL-1 | AILERON THERAPEUTICS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-9957299-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180085426-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2018-03-29 | — | — | US | disclosed |
| US-20170299576-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-9714261-B2 | Ionic liquid supported organotin reagents for the manufacturing of radiopharmaceuticals compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-07-25 | — | — | US | disclosed |
| US-7462616-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-09 | — | — | US | disclosed |
| WO-2007098963-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-09-07 | — | — | WO | disclosed |
| EP-1829866-A1 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | disclosed |
| EP-1807441-A2 | GLUCURONIDE METABOLITES AND EPIMERS THEREOF OF TIGECYCLINE | Wyeth a Corporation of the State of Delaware (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070043053-A1 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-22 | — | — | US | disclosed |
| US-7160883-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS-SQUIBB COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060128950-A1 | Glucuronide metabolites and epimers thereof of tigecycline | WYETH | 2006-06-15 | — | — | US | disclosed |
| WO-2006052717-A2 | GLUCURONIDE METABOLITES AND EPIMERS THEREOF OF TIGECYCLINE | WYETH (US) | 2006-05-18 | — | — | WO | disclosed |
| US-5948780-A | ADMINISTERING A METALLOPROTEINASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| US-5672615-A | MATRIX-DEGRADING METALLOPROTEINASE INHIBITORS | NOVARTIS CORPORATION (US) | 1997-09-30 | — | — | US | disclosed |